regarding elevation of lab parameters [GxP / QC / QA]

posted by Varsha – 2014-09-01 16:36 (4307 d 07:51 ago) – Posting: # 13447
Views: 7,421

Dear all,

We have conducted one BA BE study where at the time of screening, the volunteers were having normal ESR values but the post study safety reports after the drug administration reveals increase clinically significant ESR values and were considered as adverse event for nearly 18 subjects out of 48 subjects. The physician has documented the AE as not related to the drug as there is not linerature evidence for the same.

My concern is, is the documentation correct? What may be the reason for increase of ESR values for all these subjects.
Regards,
Varsha

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
201 visitors (0 registered, 201 guests [including 46 identified bots]).
Forum time: 00:28 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5